Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

4.4 crore health records of citizens digitized and linked with ABHA

This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting

SRL Diagnostics launches laboratory in Panchkula

The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients